NCT03253445 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bricker JB, Mann SL, Marek PM, Liu J, Peterson AV
Telephone-delivered Acceptance and Commitment Therapy for adult smoking cessation: a feasibility study. Nicotine Tob Res. 2010 Apr;12(4):454-8. doi: 10.1093/ntr/ntq002. Epub 2010 Feb 8.
Flaxman PE, Blackledge JT, Bond FW
Acceptance and commitment therapy: Distinctive features. London & New York: Routledge; 2002.
Gifford EV, Kohlenberg BS, Hayes SC, Antonuccio DO, Piasecki MM, Rasmussen-Hall ML, et al
Acceptance based treatment for smoking cessation. Behav Ther. 2004;35(4):689-705. doi: 10.1016/S0005-7894(04)80015-7. Epub 2006 Mar 3.
Gifford EV, Kohlenberg BS, Hayes SC, Pierson HM, Piasecki MP, Antonuccio DO, Palm KM
Does acceptance and relationship focused behavior therapy contribute to bupropion outcomes? A randomized controlled trial of functional analytic psychotherapy and acceptance and commitment therapy for smoking cessation. Behav Ther. 2011 Dec;42(4):700-15. doi: 10.1016/j.beth.2011.03.002. Epub 2011 May 25.
Twohig MP, Crosby JM
Acceptance and commitment therapy as a treatment for problematic internet pornography viewing. Behav Ther. 2010 Sep;41(3):285-95. doi: 10.1016/j.beth.2009.06.002. Epub 2010 Jan 28.

Individual, Acceptance and Commitment Therapy (ACT) in Smoking Cessation for People With Schizophrenia: a Randomized Controlled Trial

Clinical trial NCT03253445 - References